MA29573B1 - Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol - Google Patents

Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol

Info

Publication number
MA29573B1
MA29573B1 MA30528A MA30528A MA29573B1 MA 29573 B1 MA29573 B1 MA 29573B1 MA 30528 A MA30528 A MA 30528A MA 30528 A MA30528 A MA 30528A MA 29573 B1 MA29573 B1 MA 29573B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
carveol
carvacrol
borneol
thymol
Prior art date
Application number
MA30528A
Other languages
English (en)
French (fr)
Inventor
Adnane Remmal
Original Assignee
Advanced Scient Developments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Developments filed Critical Advanced Scient Developments
Publication of MA29573B1 publication Critical patent/MA29573B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA30528A 2005-05-13 2007-12-28 Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol MA29573B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/001314 WO2006120495A1 (fr) 2005-05-13 2005-05-13 Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol

Publications (1)

Publication Number Publication Date
MA29573B1 true MA29573B1 (fr) 2008-06-02

Family

ID=35427309

Family Applications (2)

Application Number Title Priority Date Filing Date
MA30528A MA29573B1 (fr) 2005-05-13 2007-12-28 Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol
MA30531A MA29908B1 (fr) 2005-05-13 2007-12-28 Composition pharmaceutique comprenant un agent antiparasitaire, et un actif choisi parmi le carveol, le thymol, l ugenol, le borneol, le carvacrol, l lpha-ionone ou le beta-ionone

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA30531A MA29908B1 (fr) 2005-05-13 2007-12-28 Composition pharmaceutique comprenant un agent antiparasitaire, et un actif choisi parmi le carveol, le thymol, l ugenol, le borneol, le carvacrol, l lpha-ionone ou le beta-ionone

Country Status (16)

Country Link
US (2) US20080171768A1 (https=)
EP (2) EP1879656B1 (https=)
JP (1) JP5073651B2 (https=)
CN (2) CN101175532B (https=)
AP (1) AP2437A (https=)
AT (1) ATE554827T1 (https=)
BR (2) BRPI0610123A2 (https=)
CA (2) CA2608061C (https=)
DK (2) DK1883452T3 (https=)
EA (1) EA015168B1 (https=)
ES (2) ES2386292T3 (https=)
MA (2) MA29573B1 (https=)
PT (2) PT1883452E (https=)
TN (2) TNSN07423A1 (https=)
WO (3) WO2006120495A1 (https=)
ZA (1) ZA200710785B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113042A1 (en) * 2006-09-05 2008-05-15 Chu Kee Hung Pharmaceutical composition and method for cancer treatment based on combinational use of conventional anticancer agents and geranium oil or compounds thereof
US20080293648A1 (en) * 2007-01-05 2008-11-27 Saha Pharmaceuticals, Inc. Compositions and Methods for Cancer Treatment
BRPI1009199A2 (pt) 2009-03-17 2016-03-08 Concert Pharmaceuticals Inc compostos de pirazinoisoquinolina
AU2010297406B2 (en) 2009-09-24 2013-10-17 Unilever Plc Disinfecting agent comprising eugenol, terpineol and thymol
WO2012076310A1 (en) 2010-12-07 2012-06-14 Unilever Nv An oral care composition
MX2014005405A (es) 2011-11-03 2014-06-23 Unilever Nv Una composicion de limpieza personal.
CN102579449B (zh) * 2012-03-30 2013-08-07 厦门大学 一种可提高肿瘤对紫杉醇敏感性的联合用药
GB201404505D0 (en) * 2013-09-06 2014-04-30 Mars Inc Oral anti-parasitic composition
KR20170052626A (ko) 2014-09-05 2017-05-12 심바이오믹스 세러퓨틱스 엘엘씨 세균질증 치료에 사용하기 위한 세크니다졸
CN107405404A (zh) * 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
US11253501B2 (en) 2015-06-01 2022-02-22 Lupin Inc. Secnidazole formulations and use in treating bacterial vaginosis
CN105147647A (zh) * 2015-08-19 2015-12-16 华南理工大学 右旋龙脑作为抗肿瘤药物增敏剂的应用
WO2017209588A2 (fr) 2016-06-02 2017-12-07 Advanced Scientific Developements Formulation pharmaceutique de cinéol et d'amoxicilline
CA3057858A1 (en) * 2017-03-28 2018-10-04 IRP Health Pty Ltd Berberine alkaloids in the prevention and/or treatment of intestinal disease
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof
CN112972437B (zh) * 2021-02-19 2022-03-25 沈阳伟嘉生物技术有限公司 一种包含碘硝酚的长效外用制剂及其制备方法和用途
CN121550195A (zh) * 2026-01-21 2026-02-24 哈尔滨医科大学 β-紫罗兰酮在制备肿瘤免疫调节剂中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634697A1 (de) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets Dentalwerkstoff zur bekaempfung von karies und parodontose
DE19509697A1 (de) * 1995-03-08 1996-09-12 Schering Ag Neue Borneole, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US20020182268A1 (en) * 1998-12-07 2002-12-05 Bessette Steven M. Cancer treatment compositions and method using natural plant essential oils
US6536268B1 (en) * 1999-11-01 2003-03-25 Siemens Vdo Automotive Corporation Utilizing increasing width for identification voltages
DE10007771A1 (de) * 2000-02-14 2001-08-23 Kleine & Steube Entoxin Gmbh Immunmodulatorisch wirksame Zusammensetzungen, Verfahren zu ihrer Herstellung und ihre Verwendung
US20050014827A1 (en) * 2000-11-09 2005-01-20 Schur Jorg P. Synergistic medicament containing flavoring agents and having an antagonistic regenerative and/or protagonist decontamination effect
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
ATE478684T1 (de) * 2002-02-20 2010-09-15 Ninkov Dusan Dr Antimikrobielle therapeutische zusammensetzungen und ihre verwendung
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
EA200500804A1 (ru) * 2002-12-10 2005-12-29 Биосинексус Инкорпорейтед Топические противоинфекционные композиции
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
CN100343223C (zh) * 2005-03-07 2007-10-17 常州市智能动物药业有限公司 百里酚或香芹酚的酯类化合物、制备方法及其药物活性组合物

Also Published As

Publication number Publication date
EA200702486A1 (ru) 2008-06-30
TNSN07426A1 (fr) 2009-03-17
PT1883452E (pt) 2013-02-18
TNSN07423A1 (fr) 2009-03-17
DK1883452T3 (da) 2013-02-25
BRPI0610123A2 (pt) 2012-09-25
US20080171709A1 (en) 2008-07-17
ES2399348T3 (es) 2013-03-27
WO2006120564A1 (fr) 2006-11-16
CN101193682A (zh) 2008-06-04
CN101193682B (zh) 2012-06-13
ES2386292T3 (es) 2012-08-16
CA2606887C (fr) 2014-07-15
EA015168B1 (ru) 2011-06-30
CN101175532A (zh) 2008-05-07
EP1879656B1 (fr) 2012-04-25
DK1879656T3 (da) 2012-07-23
CA2608061A1 (fr) 2006-11-16
JP5073651B2 (ja) 2012-11-14
WO2006120495A1 (fr) 2006-11-16
CA2606887A1 (fr) 2006-11-16
AP2437A (en) 2012-08-31
AP2007004228A0 (en) 2007-12-31
US20080171768A1 (en) 2008-07-17
EP1883452A2 (fr) 2008-02-06
JP2008540505A (ja) 2008-11-20
PT1879656E (pt) 2012-07-25
ATE554827T1 (de) 2012-05-15
EP1879656A1 (fr) 2008-01-23
CN101175532B (zh) 2011-12-28
EP1883452B1 (fr) 2012-12-19
CA2608061C (fr) 2014-07-15
WO2006120568A2 (fr) 2006-11-16
WO2006120568A3 (fr) 2007-08-23
MA29908B1 (fr) 2008-11-03
ZA200710785B (en) 2009-06-24
BRPI0610130A2 (pt) 2012-09-25

Similar Documents

Publication Publication Date Title
MA29573B1 (fr) Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
TNSN07425A1 (fr) Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-.
TNSN08194A1 (fr) Compositions pharmaceutiques solides contenant de la pregabaline
EP2360258A3 (en) Aprotinin polypeptides for transporting a compound across the blood-brain barrier
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
CA2176840A1 (fr) Association d'un compose a activite anti-microbienne et d'un monoalkylether de glycerol
NO20035473D0 (no) Oralt administrerte doseringsformer av GABA-analogprodrugs som har reduserttoksisitet
MA31898B1 (fr) Compositions pharmaceutiques
MA30806B1 (fr) Phosphoindoles enantiomeriquement purs utilisables en tant qu'inhibiteurs du vih
MA29387B1 (fr) Inhibiteurs de la dipeptidyl peptidase iv
TNSN08152A1 (fr) Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation
PT994710E (pt) Composicoes farmaceuticas administraveis por via oral incluindo uma benzidrilpiperazina e uma ciclodextrina
WO2006005759A3 (en) Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
WO2003059288A3 (en) Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
ATE366105T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nsaid und einen prostaglandin
MA35875B1 (fr) Dérivés d'aza-adamantane et leurs utilisations
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
WO2001074790A3 (en) Novel compounds for enhancing chemotherapy
WO2004064757A3 (en) Absorption enhancing agents
NO20064808L (no) Orale matrixformuleringer med licarbazepin
WO2007011958A3 (en) Intraoral dosage forms of glucagon
BRPI0409170A (pt) combinações compreendendo drogas antiepilépticas para o tratamento de distúrbios neurológicos
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2006039268A3 (en) Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations